Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Antineoplastic Agents, Immunological
/ adverse effects
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cross-Sectional Studies
Disease Progression
Drug Substitution
/ statistics & numerical data
Female
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Kaplan-Meier Estimate
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Nivolumab
/ adverse effects
Regression Analysis
Response Evaluation Criteria in Solid Tumors
Retrospective Studies
Disease progression
Immunotherapy
Nivolumab
Non-small cell lung cancer
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
28
04
2020
accepted:
04
07
2020
pubmed:
15
7
2020
medline:
15
9
2021
entrez:
15
7
2020
Statut:
ppublish
Résumé
This study evaluated the efficacy and safety of nivolumab treatment beyond progressive disease (PD) in non-small cell lung cancer (NSCLC). Medical records of consecutive patients with advanced NSCLC who received nivolumab between December 2015 and December 2018 were reviewed. Clinical outcomes of three groups of eligible patients who received nivolumab as a second-line treatment after PD were compared based on Response Evaluation Criteria in Solid Tumors v1.1. We conducted subgroup analyses in patients with and without new lesions at first PD. Twenty-eight patients continued nivolumab treatment beyond PD (TBP). Post PD, 46 patients switched to other anti-cancer treatment (OAT), and 21 received no further anti-cancer treatment (NAT). There were no significant differences in overall survival (OS) or survival post progression (SPP) between TBP and OAT groups (OS: 15.6 vs. 13.4 months, P = .40, SPP: 12.2 vs. 9.3 months, P = .42). Subgroup analyses indicated that among patients without new lesions at first PD, SPP was longer in the TBP than in the OAT groups (12.6 vs. 9.3 months, P = .22, HR: 0.64; 95% CI 0.31‒1.31). The frequency of immune-related adverse events leading to discontinuation during nivolumab beyond PD was equivalent to that for pre-PD (10.7 vs. 12.6%). No significant benefits were associated with continuation of nivolumab for advanced NSCLC patients. Continuation of nivolumab beyond PD could be a more useful option in patients without new lesions at first PD. Treatment-related toxicities require attention during nivolumab treatment not only before PD but also beyond PD.
Identifiants
pubmed: 32661824
doi: 10.1007/s12094-020-02452-1
pii: 10.1007/s12094-020-02452-1
doi:
Substances chimiques
Antineoplastic Agents
0
Antineoplastic Agents, Immunological
0
Immune Checkpoint Inhibitors
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
582-590Commentaires et corrections
Type : ErratumIn
Références
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2016;373:123–35. https://doi.org/10.1056/NEJMoa1504627 .
doi: 10.1056/NEJMoa1504627
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/NEJMoa1507643 .
doi: 10.1056/NEJMoa1507643
pubmed: 26412456
pmcid: 26412456
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. https://doi.org/10.1056/NEJMoa1412082 .
doi: 10.1056/NEJMoa1412082
pubmed: 25399552
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13. https://doi.org/10.1056/NEJMoa1510665 .
doi: 10.1056/NEJMoa1510665
pubmed: 26406148
pmcid: 26406148
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252 .
doi: 10.1056/NEJMoa1602252
pubmed: 27718784
pmcid: 27718784
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. New Engl J Med. 2015;372:311–9. https://doi.org/10.1056/NEJMoa1411087 .
doi: 10.1056/NEJMoa1411087
pubmed: 25482239
pmcid: 25482239
Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–94. https://doi.org/10.1016/s1470-2045(16)30167-x .
doi: 10.1016/s1470-2045(16)30167-x
pubmed: 27451390
pmcid: 27451390
Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, Zhang Y. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol. 2019;14:867–75. https://doi.org/10.1016/j.jtho.2019.01.006 .
doi: 10.1016/j.jtho.2019.01.006
pubmed: 30659987
pmcid: 30659987
Saiki M, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Horiike A. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. Lung Cancer. 2019;133:4–9. https://doi.org/10.1016/j.lungcan.2019.04.022 .
doi: 10.1016/j.lungcan.2019.04.022
pubmed: 31200826
pmcid: 31200826
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–e152152. https://doi.org/10.1016/s1470-2045(17)30074-8 .
doi: 10.1016/s1470-2045(17)30074-8
pubmed: 28271869
pmcid: 28271869
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. https://doi.org/10.1158/1078-0432.Ccr-09-1624 .
doi: 10.1158/1078-0432.Ccr-09-1624
pubmed: 19934295
pmcid: 19934295
Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15:7116–8. https://doi.org/10.1158/1078-0432.Ccr-09-2376 .
doi: 10.1158/1078-0432.Ccr-09-2376
pubmed: 19934296
pmcid: 19934296
Bohnsack O, Hoos A, Ludajic K. Adaptation of the immune related response criteria: irrecist. Ann Oncol. 2014. https://doi.org/10.1093/annonc/mdu342.23 (25:iv369-iv369).
doi: 10.1093/annonc/mdu342.23
Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Omachi N, Asami K, Okishio K, Atagi S, Okuma T. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol. 2012;7:1722–7. https://doi.org/10.1097/JTO.0b013e31826913f7 .
doi: 10.1097/JTO.0b013e31826913f7
pubmed: 23059777
pmcid: 23059777
Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;24:6195–203. https://doi.org/10.1158/1078-0432.Ccr-18-1542 .
doi: 10.1158/1078-0432.Ccr-18-1542
pubmed: 30228210
pmcid: 30228210
Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H. Nivolumab for patients with advanced melanoma treated beyond progression: Analysis of 2 Phase 3 clinical trials. JAMA Oncol. 2017;3:1511–9. https://doi.org/10.1001/jamaoncol.2017.1588 .
doi: 10.1001/jamaoncol.2017.1588
pubmed: 28662232
pmcid: 28662232
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol. 2017;72:368–76. https://doi.org/10.1016/j.eururo.2017.03.037 .
doi: 10.1016/j.eururo.2017.03.037
pubmed: 28410865
pmcid: 28410865
George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016;2:1179–86. https://doi.org/10.1001/jamaoncol.2016.0775 .
doi: 10.1001/jamaoncol.2016.0775
pubmed: 27243803
pmcid: 27243803
Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Aix SP, Rittmeyer A, Barlesi F, Kubo T, Park K. Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol. 2018;13:1906–18. https://doi.org/10.1016/j.jtho.2018.08.2027 .
doi: 10.1016/j.jtho.2018.08.2027
pubmed: 30217492
pmcid: 30217492
Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, Chiari R. Safety and efficacy of nivolumab in patients with advanced non-small-cell lung cancer treated beyond progression. Clin Lung Cancer. 2019;20(178–85):e172. https://doi.org/10.1016/j.cllc.2019.02.001 .
doi: 10.1016/j.cllc.2019.02.001
Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558–655. https://doi.org/10.1200/jco.19.00201 .
doi: 10.1200/jco.19.00201
pubmed: 31067138
pmcid: 31067138
Hu F, Li C, Xu J, Guo J, Shen Y, Nie W, Zheng X, Wang L, Zhang H, Han B, Zhang X. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. Lung Cancer. 2019;135:138–44. https://doi.org/10.1016/j.lungcan.2019.07.024 .
doi: 10.1016/j.lungcan.2019.07.024
pubmed: 31446986
pmcid: 31446986
Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y, Zhou C. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018;13:1383–92. https://doi.org/10.1016/j.jtho.2018.05.019 .
doi: 10.1016/j.jtho.2018.05.019
pubmed: 29852232
pmcid: 29852232
Petty WJ, Urbanic JJ, Ahmed T, Hughes R, Levine B, Rusthoven K, Papagikos M, Ruiz JR, Lally BE, Chan M, Clark H. Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;102:527–35. https://doi.org/10.1016/j.ijrobp.2018.06.400 .
doi: 10.1016/j.ijrobp.2018.06.400
pubmed: 30003996
pmcid: 30003996